PTO/SB/08a (09-08)

Approved for use through 10/31/2008. CMIB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Lin	der the Paperwork Reduction	ACT OF 15	995, no persons are required to re	espond to a collection of infor-	nation unless it contains a valid OMB control number	
Sut	stitute for form 1449A/PTO			Complete if Known		
				Application Number	10/729,475-Conf. #3082	
11	NFORMATION	I DI	SCLOSURE	Filing Date	December 5, 2003	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Steve PAKOLA	
				Art Unit	1651	
	(Use as many she	ets as	s necessary)	Examiner Name	T. Kim	
eet	1	of	6	Attorney Docket Number	0113476.00122US1	
	Sut	Substitute for form 1449A/PTO INFORMATION STATEMENT E (Use as many she	Substitute for form 1449A/PTO INFORMATION DI STATEMENT BY A (Use as many sheets as	Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Application Number Fixed Date First Named Inventor Art Unit Examiner Name	

			U.S. PA	TENT DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁰			
						Н			
<u> </u>						Н			
\vdash						Н			

Examiner	Date		
Signature	Cons	sidered	

*EXAMMETE Initial if reference considered, whether or not citation is in conformance with WHEP 600. Drive the through datation it is conformance and not considered. Included copy of this form with read communication to applicant. Or ICTR NO. These application(s) which are stated with an instension of the conformation in the conformation in applicant (TCTR NO. These application) are stated in the conformation of the conformation in the conformation in the conformation in the conformation in the conformation of the conformation in the conform

PTO/SB/08b (09-08)

Approved for use through 10/31/2008. OMB 0651-0031

U.S. Patent and Transmark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlines it contains a wait of 0MB control number.

Sul	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/729,475-Conf. #3082	
l In	NFORMATION	l DI	SCLOSURE	Filing Date	December 5, 2003	
l s	TATEMENT E	3Y A	APPLICANT	First Named Inventor	Steve PAKOLA	
_				Art Unit	1651	
	(Use as many she	ets as	necessary)	Examiner Name	T. Kim	
Sheet	2	of	6	Attorney Docket Number	0113476.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), delae, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Asami T, Terasaki H, Kachi S, Nakamura M, Yamamura K, Nabeshima T, and Miyake Y (2004) Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology, 111, 231-237.	
	СВ	Azzolini C, D'Angelo A, Maestranzi G, Codenotti M, Della Valle PPM, and Brancato R (2005) Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol, 139, 949-950.	
	СС	Azzolini C, D'Angelo A, Maestranzi G, Codenotti M, Della VP, Prati M, and Brancato R (2004) Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol, 138, 560-566.	
	CD	Bhisitkul RB (2001) Anticipation for enzymatic vitreolysis. Br J Ophthalmol, 85, 1-2.	
	CE	Bishop PN (2000) Structural macromolecules and supramolecular organisation of the vitreous gel. Prog Retin Eye Res, 19, 323-344.	П
	CF	Chen W, Huang X, Ma XW, Mo W, Wang WJ, and Song HY (2008) Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator. Eye, 22, 300-307.	
	CG	Chow et al. "Successful Closure Of Traumatic Macular Holes" The Journal of Retinal and Vitreous Diseases, Vol. 19, No. 5, 1999 (405-409)	
	СН	Collen, D. "Revival of Plasmin as a Therapeutic Agent?" Thromb Haemost 2001; 86: 731-2	
	CI	Foos, Robert Y. "Vitreoretinal juncture; topographical variations" Investigative Opthalmology, October 1972, Vol. 11, No. 10, (801-808)	
	CJ	Gandorfer A (2008) Experimental evaluation of microplasmin - an alternative to vital dyes. Dev Ophthalmol, 42, 153-159.	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2006. DMI 00551-0031

U.S. Patent and Trademark Office, U.S. DEPARTIMENT OF COMMERCE
Under the Paperwork Reduction Act of 1905, no persons are required to respond to a collection of informat

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/729,475-Conf. #3082	
IN.	NFORMATION	I DI	SCLOSURE	Filing Date	December 5, 2003	
s	TATEMENT E	SY A	APPLICANT	First Named Inventor	Steve PAKOLA	
				Art Unit	1651	
	(Use as many she	eets as	necessary)	Examiner Name	T. Kim	
Sheet	3	of	6	Attorney Docket Number	0113476.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	ск	Gandorfer A and Kampik A (2005) Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol, 139, 949.	
	CL	Goldberg GI, Strongin A, Collier IE, Genrich LT, and Marmer BL (1992) Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem, 267, 4583-4691.	
	СМ	Hara A (1994) Surface structure of rabbit and human retina after enzymatic separation of inner limiting membrane. Jpn J Ophthalmol, 38, 375-381.	
	CN	Hermel M and Schrage NF (2007) Efficacy of plasmin enzymes and chondroitinase ABC in creating posterior vitreous separation in the pig: a masked, placebo-controlled in vivo study. Graefes Arch Clin Exp Ophthalmol, 245, 399-406.	
	со	Jorge R, Oyamaguchi EK, Cardillo JA, Gobbi A, Laicine EM, and Haddad A (2003) Intravitreal injection of dispase causes retinal hemorrhages in rabbit and human eyes. Curr Eye Res, 26, 107-112.	
	СР	Joshi MM, Ciaccia S, Trese MT, and Capone A, Jr. (2006a) Posterior hyaloid contracture in pediatric vitreoretinopathies. Retina, 26, S38-S41.	Г
	cq	Joshi MM, Drenser K, Hartzer M, Dailey W, Capone A, Jr., and Trese MT (2006b) Intraschisis cavity fluid composition in congenital X-linked retinoschisis. Retina, 26, S57-S60.	
	CR	Khono et al. "Immunofluorescent Studies of Fibronectin and Laminin in the Human Eye" Investigate Opthalmology & Visual Science, vol. 28. March 1987. (506-514)	
	cs	Kim NJ, Yu HG, Yu YS, and Chung H (2004) Long-term effect of plasmin on the vitreolysis in rabbit eyes. Korean J Ophthalmol, 18, 35-40.	Г
	ст	Laryukhina GM and Ziangirova GG (1977) Experimental enzymatic vitreolysis. Vestn Oftalmol (6) 76-79.	Г

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2006. DMI 00551-0031

U.S. Patent and Trademark Office, U.S. DEPARTIMENT OF COMMERCE
Under the Paperwork Reduction Act of 1905, no persons are required to respond to a collection of informat

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/729,475-Conf. #3082	
11	VEORMATION	I DI	SCLOSURE	Filing Date	December 5, 2003	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Steve PAKOLA	
_				Art Unit	1651	
	(Use as many sh	eets as	necessary)	Examiner Name	T. Kim	
Sheet	4	of	6	Attorney Docket Number	0113476.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CU	Li X, Shi X, and Fan J (2002) Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol, 240, 56-62.	
	cv	Marder et al. "Plasmin Induces Local Thromolysis Without Causing Hemorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit" Thromb Haemost 2001; 86: 739-45	
	cw	Moser TL, Enghild JJ, Pizzo SV, and Stack MS (1993) The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem, 268, 18917-18923.	
	сх	Okajima K, Abe H, and Binder BR (1995) Endothelial cell injury induced by plasmin in vitro. J Lab Clin Med, 126, 377-384.	
	CY	Powell JR and Castellino FJ (1980) Activation of human neo-plasminogen-Val442 by urokinase and steptokinase and a kinetic characterization of neoplasmin-Val442. J Biol Chem, 255, 5329-5335.	
	cz	Proksch JW, Driot JY, Vandeberg P, and Ward KW (2008) Nonclinical safety and pharmacokinetics of intravitreally administered human-derived plasmin in rabbits and minipigs. J Ocul Pharmacol Ther, 24, 320-332	Г
	CA1	Quiram PA, Leverenz VR, Baker RM, Dang L, Giblin FJ, and Trese MT (2007) Microplasmin- induced posterior vitreous detachment affects vitreous oxygen levels. Retina, 27, 1090-1096.	П
	CB1	Rizzo S, Pellegrini G, Benocci F, Belting C, Baicchi U, and Vispi M (2006) Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery. Retina, 26, 792-796.	
	CC1	Sakuma et al. "Efficacy of autologous plasmin for idiopathic macular hole surgery" 2005 (Eur J Opthalmol 15, 787-794)	
	CD1	Sakuma T, Tanaka M, Inoue J, Mizota A, Souri M, and Ichinose A (2006) Use of autologous plasmin during vitrectomy for diabetic maculopathy. Eur J Ophthalmol, 16, 138-140.	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 1031/2006. (104-03)

Approved for use through 1031/2006. (106-03)

U.S. Patient and Trademark Office, U.S. DEPARTIMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information united is continu

Substitute for form 1449/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/729,475-Conf. #3082	
				Filing Date	December 5, 2003	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Steve PAKOLA	
				Art Unit	1651	
(Use as many sheets as necessary)			necessary)	Examiner Name	T. Kim	
Sheet	5	of	6	Attorney Docket Number	0113476.00122US1	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T ²		
	CE1	Sebag J (1998) Pharmacologic vitreolysis. Retina, 18, 1-3.			
	CF1	Sebag J (2002) Is pharmacologic vitreolysis brewing Retina, 22, 1-3.			
	CG1	Sebag J (2005) Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc, 103, 473-494.	Г		
CH1 Sebag J and Balazs EA (1989) Morphology and ultrastructure of human vitreous fibers. Inve					
Cl1 Sebag J, Ansari RR, and Suh KI (2007) Pharmacologic vitreolysis with microplasmin vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol, 245, 576-580.					
CJ1		Shapiro SD, Fliszar CJ, Broekelmann TJ, Macham RP, Senior RM, and Welgus HG (1995) Activation of the 92-kD a gelatinase by stromelysin and 4-aminophenylmeruria caetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem. 270, 6351-6356.			
	CK1	Stack MS, Moser TL, and Pizzo SV (1992) Binding of human plasminogen to basement- membrane (type IV) collagen. Biochem J, 284, 103-108.			
CL1 eye		Staubach F, Nober V, and Janknecht P (2004) Enzyme-assisted vitrectomy in enucleated pig eyes: a comparison of hyaluronidase, chondroitinase, and plasmin. Curr Eye Res, 29, 261-268.			
	СМ1	Takano A, Hirata A, Inomata Y, Kawaji T, Nakagawa K, Nagata S, and Tanihara H (2005) Intravitreal plasmin injection activates endogenous matrix metalloproteinase-2 in rabbit and human vitreous. Am J Ophthalmol, 140, 654-660.			
·	CN1	Takano A, Hirata A, Ogasawara K, Sagara N, Inomata Y, Kawaji T, and Tanihara H (2006) Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis. Invest Ophthalmol Vis Sci, 47, 2075-2079.			

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2006. DMI 00551-0031

U.S. Patent and Trademark Office, U.S. DEPARTIMENT OF COMMERCE
Under the Paperwork Reduction Act of 1905, no persons are required to respond to a collection of information unless its contains a valid OMS control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/729,475-Conf. #3082	
IN.	IFORMATION	I DI	SCLOSURE	Filing Date	December 5, 2003	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Steve PAKOLA	
				Art Unit	1651	
(Use as many sheets as necessary)			necessary)	Examiner Name	T. Kim	
Sheet	6	of	6	Attorney Docket Number	0113476.00122US1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CO1	Trese MT (2000) Enzymatic vitreous surgery. Semin Ophthalmol, 15, 116-121.	
	CP1	Wang F, Wang Z, Sun X, Wang F, Xu X, and Zhang X (2004) Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest Ophthalmol Vis Sci, 45, 3286-3290.	
	CQ1	Wang ZL, Zhang X, Xu X, Sun XD, and Wang F (2005) PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina, 25, 38-43.	
	CR1	Wu HL, Shi GY, and Bender ML (1987) Preparation and purification of microplasmin. Proc Natl Acad Sci U S A, 84, 8292-8295.	
	CS1	Wu WC, Drenser KA, Capone A, Williams GA, and Trese MT (2007a) Plasmin enzyme- assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system. Retina, 27, 1079-1085.	
	CT1	Wu WC, Drenser KA, Trese MT, Williams GA, and Capone A (2007) Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy. Am J Ophthalmol, 144, 668-672.	
	CU1	Suenson, Elisabeth and Thorsen, Sixtus. "Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin" Biochem. J. (1981) 197, 619-628	Г
	CV1	Gonias, Steven and Figler, Nancy. " α 2-Macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse" Biochem. J. (1988) 255, 725-730.	
			F

Examiner	/Taeyoon Kim/	Date	12/02/2008
Signature	/ racycon rains	Considered	12,02,2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.